Regenxbio Inc. (NASDAQ:RGNX)’s share price traded down 5.6% during trading on Wednesday . The company traded as low as $14.72 and last traded at $15.05, with a volume of 214,553 shares. The stock had previously closed at $15.95.

A number of equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Regenxbio from a “sell” rating to a “hold” rating in a research note on Friday, August 26th. Piper Jaffray Cos. set a $25.00 price objective on shares of Regenxbio and gave the stock a “buy” rating in a research note on Thursday, August 18th. Finally, Chardan Capital restated a “buy” rating on shares of Regenxbio in a research note on Monday, August 22nd. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $26.75.

The stock’s market capitalization is $404.12 million. The stock’s 50 day moving average is $12.12 and its 200 day moving average is $10.93.

Regenxbio (NASDAQ:RGNX) last released its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.02. Regenxbio had a negative net margin of 451.73% and a negative return on equity of 17.89%. Analysts predict that Regenxbio Inc. will post ($2.37) earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the stock. Perceptive Advisors LLC increased its stake in Regenxbio by 33.2% in the second quarter. Perceptive Advisors LLC now owns 1,099,213 shares of the company’s stock valued at $8,793,000 after buying an additional 273,817 shares during the period. Vivo Capital LLC bought a new stake in Regenxbio during the first quarter valued at $10,697,000. Franklin Resources Inc. increased its stake in Regenxbio by 1,004.9% in the second quarter. Franklin Resources Inc. now owns 700,500 shares of the company’s stock valued at $5,604,000 after buying an additional 637,100 shares during the period. BlackRock Advisors LLC increased its stake in Regenxbio by 27,318.5% in the second quarter. BlackRock Advisors LLC now owns 687,657 shares of the company’s stock valued at $5,501,000 after buying an additional 685,149 shares during the period. Finally, Vanguard Group Inc. increased its stake in Regenxbio by 116.4% in the second quarter. Vanguard Group Inc. now owns 569,935 shares of the company’s stock valued at $4,559,000 after buying an additional 306,596 shares during the period. 68.73% of the stock is owned by hedge funds and other institutional investors.

About Regenxbio

REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

5 Day Chart for NASDAQ:RGNX

Receive News & Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.